Investments
1Partners & Customers
5About Boryung Pharmaceutical
Boryung Pharmaceutical (KRX: 003850) is a pharmaceutical company in South Korea fully integrated from R&D through manufacturing, marketing, and sales. The company has focused on the development and commercialization of new pharmaceutical products. Its main therapeutic categories are oncology, cardiovascular, anti-infective, and respiratory system.
Boryung Pharmaceutical Headquarter Location
136, Changgyeonggung-ro Jongno-gu
Seoul, 03127,
South Korea
Latest Boryung Pharmaceutical News
Apr 20, 2022
Boryung opens CIS challenge to find healthcare solutions in space 바로가기 기자명 Kim Chan-hyuk 닫기 Boryung Pharmaceutical said it would open the first Care In Space (CIS) Challenge, a global competition event to find technologies and solutions for human health in space. Boryung leads the CIS challenge in collaboration with Axiom Space, an American human spaceflight services provider, and Starbust, a global aerospace startup accelerator. “As the era of space travel began recently, human activities are expected to get livelier in gravity-free space. Therefore, to preemptively respond to potential changes in human health in outer space, we have been preparing for the CIS project since 2020,” Boryung said. The CIS Challenge is part of the CIS project. Boryung said the challenge aimed to gather aerospace healthcare startups and those with creative ideas eager to find solutions to address various potential healthcare issues in space. Boryung will receive global participants’ applications and screen their ideas for the next three months. On July 28, a Pitch Day event will have selected applicants showcase their ideas at the UCLA Conference Hall. Then, on Demo Day in December, selected teams will have an opportunity to explain their ideas and solutions to investors worldwide. During the challenge period, experts from aerospace companies in the U.S. and Israel and major universities such as Stanford, Harvard, MIT, and Georgia Tech will verify ideas and provide tailored mentoring for business development. Details about the CIS challenge are available at cischallenge.com or Boryung’s website. Lim Dong-joo, head of the New Portfolio Investment Team at Boryung’s Global Investment Center, said the company would hold the CIS challenge annually to lead responses to healthcare issues in space. “We will discover new investment opportunities and establish ourselves as a must-have global partner in aerospace medicine,” he said.
Boryung Pharmaceutical Investments
1 Investments
Boryung Pharmaceutical has made 1 investments. Their latest investment was in ViGenCell as part of their Corporate Minority on July 7, 2016.
Boryung Pharmaceutical Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
7/28/2016 | Corporate Minority | ViGenCell | $1.33M | Yes | 4 |
Date | 7/28/2016 |
---|---|
Round | Corporate Minority |
Company | ViGenCell |
Amount | $1.33M |
New? | Yes |
Co-Investors | |
Sources | 4 |
Boryung Pharmaceutical Acquisitions
2 Acquisitions
Boryung Pharmaceutical acquired 2 companies. Their latest acquisition was Forbio Korea - Research Unit on February 08, 2022.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
2/8/2022 | Acquired Unit | 1 | ||||
8/10/2017 | Series B |
Date | 2/8/2022 | 8/10/2017 |
---|---|---|
Investment Stage | Series B | |
Companies | ||
Valuation | ||
Total Funding | ||
Note | Acquired Unit | |
Sources | 1 |
Boryung Pharmaceutical Partners & Customers
5 Partners and customers
Boryung Pharmaceutical has 5 strategic partners and customers. Boryung Pharmaceutical recently partnered with Almirall on January 1, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
1/21/2022 | Licensor | Spain | Boryung to market Almirall's spray-type hair loss treatment in Korea Boryung Pharmaceutical said that it has signed a sales contract with Almirall for Finjuve , a spray-type finasteride-based hair loss treatment , in Korea . | 1 | |
2/24/2021 | Licensor | ||||
1/1/2018 | Licensor | ||||
9/27/2017 | Licensor | ||||
1/7/2013 | Licensee |
Date | 1/21/2022 | 2/24/2021 | 1/1/2018 | 9/27/2017 | 1/7/2013 |
---|---|---|---|---|---|
Type | Licensor | Licensor | Licensor | Licensor | Licensee |
Business Partner | |||||
Country | Spain | ||||
News Snippet | Boryung to market Almirall's spray-type hair loss treatment in Korea Boryung Pharmaceutical said that it has signed a sales contract with Almirall for Finjuve , a spray-type finasteride-based hair loss treatment , in Korea . | ||||
Sources | 1 |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.